Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
2.490
+0.240 (10.67%)
At close: Mar 25, 2026, 4:00 PM EDT
2.480
-0.010 (-0.40%)
Pre-market: Mar 26, 2026, 9:00 AM EDT

Moleculin Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-33.56-26.05-29.77-29.03-15.89
Depreciation & Amortization
0.090.130.130.130.16
Stock-Based Compensation
1.661.730.772.282.37
Other Adjustments
8.520.11.67-1.24-6.63
Changes in Accounts Payable
1.33-0.470.40.730.24
Changes in Accrued Expenses
0.02-1.111.490.350.37
Changes in Other Operating Activities
-0.791.81-0.27-0.860.43
Operating Cash Flow
-22.74-23.86-23.59-27.64-18.95
Capital Expenditures
--0.01-0.12-0.07-0.02
Investing Cash Flow
--0.01-0.12-0.07-0.02
Issuance of Common Stock
27.294.664.17-74.75
Repurchase of Common Stock
-0.01-0.03-0.03-0.02-0.02
Net Common Stock Issued (Repurchased)
27.284.644.14-0.0274.72
Financing Cash Flow
27.284.644.14-0.0274.72
Effect of Exchange Rate Changes on Cash and Cash Equivalents
0.05-0.03-0.02-0.03-0.02
Net Cash Flow
4.6-19.27-19.6-27.7655.73
Free Cash Flow
-22.74-23.88-23.72-27.71-18.97
Free Cash Flow Per Share
-19.19-173.36-300.10-363.22-264.69
Levered Free Cash Flow
-66.58-51.75-28.14-28.74-14.71
Unlevered Free Cash Flow
-24.46-26.3-28.01-30.35-21.79
Updated Mar 18, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q